Bessemer Group
AXSM icon

Bessemer Group’s Axsome Therapeutics AXSM Stock Holding History

Bessemer Group’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$242K Sell
1,428
-8
-0.6% -$1.38K ﹤0.01% 1349
2025
Q4 		$262K Buy
1,436
+21
+1% +$2.93K ﹤0.01% 1300
2025
Q3 		$172K Buy
1,415
+1,280
+948% +$144K ﹤0.01% 1159
2025
Q2 		$14K Buy
135
+110
+440% +$11.6K ﹤0.01% 1673
2025
Q1 		$3K Sell
25
-5
-17% -$570 ﹤0.01% 2131
2024
Q4 		$3K Hold
30
– – ﹤0.01% 2109
2024
Q3 		$3K Buy
+30
New +$2.62K ﹤0.01% 2063

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bessemer Group's AXSM Position: Q1 2026 in Review

Bessemer Group reduced its Axsome Therapeutics (AXSM) stake by 0.56% in Q1 2026, selling an estimated $1.38K and leaving 1,428 shares worth $242K. The position accounts for ﹤0.01% of the portfolio, ranked #1349.

Bessemer Group first reported a position in AXSM in Q3 2024 and has held it in 7 quarters since. The position peaked at $262K in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Bessemer Group held 1,428 shares of Axsome Therapeutics worth $242K as of Q1 2026.
  • Bessemer Group sold 8 Axsome Therapeutics shares in Q1 2026, an estimated $1.38K.
  • Axsome Therapeutics made up ﹤0.01% of Bessemer Group's portfolio in Q1 2026, its #1349 holding.
  • Bessemer Group first reported a position in Axsome Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Bessemer Group's Axsome Therapeutics position peaked at $262K in Q4 2025.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Bessemer Group's 13F filing for Q1 2026, filed 6 May 2026.